Results 161 to 170 of about 69,360 (221)

Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies

MedComm, Volume 6, Issue 8, August 2025.
Mechanisms of alleviating resistance to PD‐1/PD‐L1 blockade by IFN‐α and IFN‐β. In these mechanisms, the “yin‐yang balance” is disrupted, thus preventing T cells from attacking cancer cells. Restoring this balance may improve the efficacy of anti‐PD‐1/PD‐L1 therapy and reinvigorate T cells and other immune cells to target and destroy cancer cells ...
Peng Gao, Xiao Li, Zhenyu Duan, Yang Wang, Yinggang Li, Jing Wang, Kui Luo, Jie Chen   +7 more
wiley   +1 more source

Power of Memory: A Natural Killer Cell Perspective. [PDF]

Cells
Sinha O, Abhipsha SK, Sen Santara S.
europepmc   +1 more source

PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment

MedComm, Volume 6, Issue 8, August 2025.
The PI3K/AKT/mTOR signaling axis is crucial in cancer progression, regulating cell growth, survival, and metabolism. Often hyperactivated through mutations or loss of tumor suppressors such as PTEN, this pathway promotes cancer cell proliferation and survival by inhibiting apoptosis and activating mTOR, which drives protein synthesis and suppresses ...
Mingyang Jiang, Ke Zhang, Zhenwang Zhang, Xinran Zeng, Zihang Huang, Peizhuo Qin, Zhilin Xie, Xue Cai, Milad Ashrafizadeh, Yu Tian, Ruqiong Wei   +10 more
wiley   +1 more source

Characterization of Murine Leukemia Virus-specific Proteins

Cold Spring Harbor Symposia on Quantitative Biology, 1974
H. Ikeda, Elisabeth Stockert, T. Pincus, Ellen S. Vitetta, E. Tress, Paul V. O'Donnell, W. Hardly, W. Fleissner, Jwu Sheng Tung, Edward A. Boyse   +9 more
openaire   +3 more sources

The reprogramming factor KLF4 in normal and malignant blood cells. [PDF]

Front Immunol
Lacorazza HD.
europepmc   +1 more source

Two-Year Surveillance of Dengue, Zika, and Chikungunya Viruses Among Chinese Blood Donors - Guangxi and Yunnan PLADs, China, 2022-2023. [PDF]

China CDC Wkly
Yan Y, Liu X, Lu S, Chang L, Dong J, Ji H, Sun H, Wang L.   +7 more
europepmc   +1 more source

Toll‐Like Receptors in the Immunotherapy Era: Dual‐Edged Swords of Tumor Immunity and Clinical Translation

MedComm, Volume 6, Issue 8, August 2025.
This review discussed the signaling pathways of Toll‐like receptors in tumors and their antitumor or protumor regulatory effects in diverse tumors. We also paid attention to the application of Toll‐like receptors in clinical treatment and summarized the clinical trial situation in recent years.
Nueraili Maihemuti, Yueli Shi, Kaiyue Zhang, Xinyuan Jiang, Jiahe Chu, Yun Xu, Zhiyong Xu, Kai Wang   +7 more
wiley   +1 more source

Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site. [PDF]

iScience
Wang LL, Keiser P, Yang D, Seravalli J, Patten JJ, Eaton B, Anderson D, Liu Y, Holbrook MR, Smith AB, Davey RA, Xiang SH.   +11 more
europepmc   +1 more source

The TP53 tumor suppressor gene: From molecular biology to clinical investigations

Journal of Internal Medicine, Volume 298, Issue 2, Page 78-96, August 2025.
Abstract Extensively studied over the past four decades, the TP53 gene has emerged as a pivotal watchman in cellular defense and a key factor in cancer biology. TP53 is the most frequently mutated gene in human malignancies, 50% of which carry alterations to it.
Panagiotis Baliakas, Thierry Soussi
wiley   +1 more source

Current developments in T-cell receptor therapy for acute myeloid leukemia. [PDF]

Blood Adv
Gore S, Blyth E, Bleakley M, Lee K, Micklethwaite K, Gowrishankar K.   +5 more
europepmc   +1 more source